Table 3 Vaccine candidates based on rabies virus vector
Pathogens | Design strategy | Stage | Results | Advantages | Overall concerns | Reference |
|---|---|---|---|---|---|---|
Ebola virus | BNSP333-GP | NHPs | 100% protection | \ | Poor NAbs; safety concern | |
INACBNSP333-GP | NHPs | 50% protection | Safe | Poor NAbs | ||
INACBNSP333 co (EBOV + SUDV + MARV) GP | NHPs | 100% protection | Safe; immunogenic; high titer of NAbs | \ | ||
rERAG333E-(EBOV + SUDV) GP | Dogs | NAbs and specific Abs | Long-term protection (1 year); oral delivery | Safety concern | ||
Marburg virus | INACBNSP333-coGPC | Mice | 100% protection | Safe | Poor NAbs | |
Lassa virus | BNSP333-coGPC | Guinea pigs | 40% protection | \ | Poor binding IgGs | |
BNSPΔG-coGPC | Mice | \ | \ | Poor binding IgGs | ||
INACBNSP333-coGPC | Guinea pigs | 80% protection | Safe | No NAbs | ||
RVFV | rSRV9-eGn | Mice | \ | Safe | Poor NAbs | |
MERS-CoV | INACBNSP333-S1 | Mice | 100% protection | High titer of NAbs; safe | \ | |
RVΔP-S1 | Mice | NAbs | Safe | \ | ||
INACrSRV9-S1 | Mice | \ | Earlier humoral and cellular immunity | \ | ||
SARS-CoV | pSPBN-333-S | Mice | Binding Abs and NAbs | \ | \ | |
SARS-CoV-2 | BNSP333-S1 | Golden hamsters | NAbs and reduced virus load | Single dose; safe; long-lasting immune response | \ | |
rSRV9-RBD/S1 | Mice, cats and dogs | NAbs against SARS-CoV-2 and RABV | Long-lasting antibody response (4 months); broad-spectrum immune response | \ | ||
Nipah virus | INACBNSP333-G | Mice | G-specific Abs and NAbs | Cross-protection | \ | |
BNSP333-G | Mice | G-specific Abs and NAbs | \ | \ | ||
rERAG333E-G/F | Mice and Pigs | G/F-specific Abs and NAbs | Oral delivery | \ | ||
Hendra virus | BNSP333-coG | Mice | G-specific Abs and NAbs | \ | Poor G-specific Abs | |
INACBNSP333-coG | Mice | G-specific Abs and NAbs | More immunogenic than RABV vector-based live vaccines | \ |
